
Commentary|Videos|May 5, 2024
Dr. Dmochowski on tibial nerve stimulation as an earlier line of therapy for OAB
Author(s)Urology Times staff
Roger R. Dmochowski, MD, MMHC, highlights the FDA approval of the Revi System, specifically touching on how the device may be used as a potential earlier line of therapy for patients with OAB.
Advertisement
In this video, Roger R. Dmochowski, MD, MMHC, highlights the FDA approval of the BlueWind Revi System, specifically touching on how the device is being recognized as a potential earlier line of therapy for patients with overactive bladder (OAB). Dmochowski is the chief medical officer at BlueWind Medical as well as a professor of urology, gynecology, and surgery and Vanderbilt University Medical Center in Nashville, Tennesee.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
HHS requests testosterone therapy label updates, citing new safety data
2
Unmet needs and emerging solutions in MRI-guided prostate cancer care
3
Enzalutamide plus talazoparib demonstrates clinical activity in mHSPC
4
Mina Fam, MD, highlights significance of tebipenem pivoxil approval for cUTI
5













